Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 12,701–12,800 of 15,747
Sengsayadeth, S. M., Broglie, L. A., & Savani, B. N. (2021) · British Journal of Haematology · doi:10.1111/bjh.17955 · Cited by 1
Huang, J., Sun, Q., Zhong, Y., & Huang, J. (2026) · Archives of Microbiology · doi:10.1007/s00203-026-04928-0 · Cited by 1
Complexation of siRNA with Galactose-Functionalized Dendrimers: PAMAM vs PETIM
Maity, T., Kumar, Y., & Maiti, P. K. (2025) · Langmuir · doi:10.1021/acs.langmuir.5c03613 · Cited by 1
Kubinec, R. (2020) · SocArXiv (OSF Preprints) · doi:10.31235/osf.io/a492b · Cited by 1
ScRNA-Seq Reveals T Cell Immunity in COVID-19 Patients and Implications for ImmunotherapyPreprint
Zhang, B., Feng, Z., Jiao, A., & Zhang, H. (2024) · doi:10.22541/au.170663818.80204228/v1 · Cited by 1
Faissner, S., Heitmann, N., Rohling, R., Ceylan, U., Bongert, M., Marheinecke, C. S., Pedreiturria, X., Ayzenberg, I., Hellwig, K., Schmitz, I., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-1109886/v1 · Cited by 1
Engineered Migrasomes: A Robust, Thermally Stable Vaccination PlatformPreprint
Wang, D., Wang, H., Wan, W., Zhu, Z., Sho, T., Zheng, Y., Zhang, X., Dou, L., Ding, Q., Yu, L., et al. (2024) · eLife · doi:10.7554/elife.97621.1 · Cited by 4
Complications after administration of mRNA vaccine against COVID-19 - case report and short review
Varga, I., Michalka, P., & Mištinová, J. P. (2023) · Vnitřní lékařství · doi:10.36290/vnl.2023.054 · Cited by 1
A review of COVID-19 vaccines strategies and anti-vaxxers theories
Adesokan, A. M., & Obeid, M. A. (2021) · African Journal of Clinical and Experimental Microbiology · doi:10.4314/ajcem.v22i2.3 · Cited by 1
Li, M., Ma, S., Shen, M., Wan, R., Long, J., Jiang, Y., Liang, H., Guo, Z., Ma, X., & Song, W. (2026) · Science China Materials · doi:10.1007/s40843-025-3634-0 · Cited by 3
“Lipid nanoparticles (LNPs) have underpinned the success of mRNA vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), with over one billion doses administered worldwide, making them the most clinically utilized nanoparticle platform to date [1,2].”
(2023) · doi:10.1101/2023.10.18.563006 · Cited by 1
“…is a major component (≈40 mol% of the lipid mixture) in the LNP formulations of the approved siRNA therapeutic OnPattro™ (patisiran) [55] and the mRNA vaccines against SARS-CoV-2 [56-59] and is frequently used as a major component in liposomal formulations for the delivery of hydrophilic drugs.”
BackgroundExploring the treatment of SARS-CoV-2 with modified vesicular stomatitis virus
Polavarapu, N., Doty, M., & Dobrovolny, H. M. (2024) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2024.111959 · Cited by 1
Nazar, G., Olszlegier, J., Kamińska, A., Plata‐Nazar, K., & Nazar, W. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14186542 · Cited by 1
“However, it has been reported that some individuals, including children, may experience post-vaccination ADRs [17,18,21].”
Fujii, Y. R. (2021) · Advancements in Case Studies · doi:10.31031/aics.2021.03.000552 · Cited by 2
Using machine learning probabilities to identify effects of COVID-19
Ramlall, V., Gisladottir, U., Kefeli, J., Tanaka, Y., May, B. L., & Tatonetti, N. P. (2023) · Patterns · doi:10.1016/j.patter.2023.100889 · Cited by 2
Evaluation of serum and cerebrospinal fluid biomarkers after vaccination against SARS‐CoV ‐2
Iacono, S., Piccoli, T., Aridon, P., Schirò, G., Blandino, V., Tarantino, D., Agnello, L., Ciaccio, M., Ragonese, P., & Salemi, G. (2023) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51785 · Cited by 1
Determination of early side effects after covid-19 vaccinations
Şimşek, N. Y., Açıksöz, S., & Atar, N. Y. (2023) · Acibadem Universitesi Saglik Bilimleri Dergisi · doi:10.31067/acusaglik.1109356 · Cited by 1
How to Explain Vaccination to Your Unvaccinated Patients
Shafer, S. L. (2021) · ASA Monitor · doi:10.1097/01.asm.0000798480.52197.38 · Cited by 1
Accelerated vaccine process development by orthogonal protein characterization
James, D. A., Szymkowicz, L., Yin, L., Shah, H., Leach, M., & Chicz, R. M. (2025) · Scientific Reports · doi:10.1038/s41598-025-96642-y · Cited by 2
MODERN METHOD OF SARS-CоV-2 COMBAT
Bobkova, N. V., Полтавцева, Р. А., Chaplygina, A. V., Sadykov, V. F., Sukhikh, G. T., & Sukhikh, G. T. (2023) · Molekulyarnaya Meditsina (Molecular medicine) · doi:10.29296/24999490-2023-01-03 · Cited by 1
Evolution of antibody profiles against SARS-CoV-2 in experienced and naïve vaccinated elderly people
Sanz-Muñoz, I., López-Mongil, R., Sánchez‐Martínez, J., Prada, L. S.-D., González, M. D., José, D. P. S., Rojo‐Rello, S., Hernán-García, C., Espinilla, V. F., de Lejarazu-Leonardo, R. O., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1128302 · Cited by 2
“Vaccines reduce the risk of severe and complicated COVID-19 infection (17, 18).”
BackgroundChow, J. Y., Goh, Z. J., Li, R., Lim, D. Z. Y., Wee, L. E., Lye, D. C., Tan, K. B., & Lim, J. T. (2025) · medRxiv · doi:10.1101/2025.09.29.25336864 · Cited by 1
A Mathematical Model for the COVID-19 Pandemic in Tokyo through Changing Point Calculus
Martinez-Vazquez, L., & Casas, P. F. I. (2023) · Applied Sciences · doi:10.3390/app132212252 · Cited by 1
Devang, N., Banjan, B., V.K., P., Raju, R., Kochupurackal, J., & E.K., R. (2025) · Next research. · doi:10.1016/j.nexres.2025.100201 · Cited by 1
Estrategia de vacunación en México y diversidad de vacunas.
Noriega-Rubalcaba, A., Nieto-Ortega, E., Vivanco-Gómez, E., Durán-Méndez, A., Ortega, D. P., & Peón, A. N. (2021) · doi:10.46295/2:1.correc · Cited by 1
Simultaneous and sequential multi-species coronavirus vaccinationPreprint
Peng, L., Fang, Z., Renauer, P. A., McNamara, A., Park, J. J.-Y., Lin, Q., Zhou, X., Dong, M. B., Zhu, B., Zhao, H., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.05.07.491038 · Cited by 1
“The most prominent and efficacious vaccine belong to the lipid nanoparticle (LNP) mRNA vaccine category, with the first two emergency use approval issued to Moderna and Pfizer-BioNTech mRNA vaccines 17,18 .”
BackgroundInfluentialKunath, P., Pflumm, D., Moehrle, B., Sakk, V., Seidel, A., Münch, J., Geiger, H., & Schirmbeck, R. (2025) · Immunity & Ageing · doi:10.1186/s12979-025-00507-x · Cited by 1
Aggregating probabilistic predictions of the safety, efficacy, and timing of a COVID-19 vaccine
(2021) · doi:10.1101/2021.06.03.21258240 · Cited by 1
“2020 of the efficacy of a vaccine approved under emergency authorization was 50%, greatly underestimating the 95% efficacy of the Pfizer/BioNTech vaccine [29].”
BackgroundCarnero, M., Cuerpo, G., Menéndez, J. L., et al. (2023) · Cirugía Cardiovascular · doi:10.1016/j.circv.2023.04.003 · Cited by 1
Evaluation of the Abdala Vaccine: Antibody and Cellular Response to the RBD Domain of SARS-CoV-2
Islas-Vázquez, L., Alvarado-Alvarado, Y. C., Cruz‐Aguilar, M., Velázquez-Soto, H., Villalobos-Gonzalez, E., Ornelas-Hall, G., Pérez‐Tapia, S. M., & Martínez, M. D. C. J. (2023) · Vaccines · doi:10.3390/vaccines11121787 · Cited by 2
Campise, M., Alfieri, C., Benedetti, M., Perna, A., Miglio, R., Molinari, P., Cervesato, A., Giuliani, S., Gandolfo, M. T., Regalia, A. L., et al. (2022) · Vaccines · doi:10.3390/vaccines10070990 · Cited by 1
Yıldız, R., & Nişancı, O. S. (2025) · The Turkish Journal of Geriatrics · doi:10.29400/tjgeri.2025.454 · Cited by 1
Yoshifuji, A., Toda, M., Ryuzaki, M., et al. (2022) · Preprints.org · doi:10.20944/preprints202209.0101.v1 · Cited by 1
Heng, F., Sun, Y., Li, L., & Gilbert, P. B. (2025) · Statistics in Medicine · doi:10.1002/sim.10345 · Cited by 6
Off-Label use of vaccines may save lives and money: lessons from the province of Quebec, Canada
Wals, P. D., & Quach, C. (2025) · Expert Review of Vaccines · doi:10.1080/14760584.2025.2589214 · Cited by 1
Respiratory protection: what SARS-CoV-2 has taught us
Loeb, M. B. (2023) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000930 · Cited by 1
Navarro-Olivos, E., Magos-Vázquez, F. J., Sánchez-Navarro, M. D. R., Díaz-Martínez, D. A., Gallardo-Luna, M. D. J., & Raygoza, N. P. (2022) · Biomedical & Pharmacology Journal · doi:10.13005/bpj/2435 · Cited by 1
Yoon, S., Cho, H.-G., Lee, J., Ha, S., Lee, S., Lee, Y., Cho, Y., Ha, D., Oh, A., Lee, S., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2025.12.060 · Cited by 6
“20,28 Of note, this 5 ′ UTR sequence was also used in other applications, including mPDL1.”
House, T., Pellis, L., Pritchard, E., et al. (2021) · arXiv (Cornell University) · doi:10.48550/arxiv.2107.06545 · Cited by 1
Robust immune response to COVID-19 vaccination in the island population of Greenland
Møller, M., Friis-Hansen, L. J., Kirkby, N. S., Dilling-Hansen, C., Andersson, M., Vedsted, P., Mølbak, K., & Koch, A. (2024) · Communications Medicine · doi:10.1038/s43856-024-00602-y · Cited by 1
In Silico Identification of Potential Inhibitors of SARS-CoV-2 Main Protease (Mpro)
Hernández‐Serda, M. A., Vázquez‐Valadez, V. H., Aguirre-Vidal, P., Markarian, N. M., Medina‐Franco, J. L., Cárdenas‐Granados, L. A., Alarcón‐López, A. Y., Martínez‐Soriano, P. A., Velázquez‐Sánchez, A. M., Falfán-Valencia, R., et al. (2024) · Pathogens · doi:10.3390/pathogens13100887 · Cited by 1
“Currently, there are many ways to control the COVID-19 pandemic: vaccines [24,25], neutralizing monoclonal antibodies (mAbs) against the spike protein, and the antiviral drugs ritonavir-boosted nirmatrelvir (targeting the M pro ) [26], molnupiravir, and remdesivir (both targeting RNA-dependent RNA…”
BackgroundPEG Gels Significantly Improve the Storage Stability of Nucleic Acid Preparations
Cui, P., Ma, L., Jiang, P., Wang, C., & Wang, J. (2022) · Gels · doi:10.3390/gels8120819 · Cited by 1
Bibliometric analysis of the highly cited publications in COVID-19 vaccine
Yan, L., & Liu, L. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e18540 · Cited by 4
Bawazir, W. M. S., Ibad, A. A., Mohsin, M., Niyazi, H. A., Alamri, T. A., Bazuhair, M. A., Hazzazi, M. S., Chehab, N. A., Harakeh, S., & Yousafzai, Y. M. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1615227 · Cited by 1
State-of-the-Art Cancer Immunotherapies
Nagase, H., Kato, T., & Yoshimoto, T. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052532 · Cited by 1
“The delivery of COVID-19 mRNA vaccines manufactured by Moderna [9] and Pfizer [3] was successfully achieved using LNPs.”
MethodOhrnberger, S., zu Natrup, C. M., Clever, S., Schünemann, L.-M., Armando, F., Ciurkiewicz, M., Baumgärtner, W., Kalodimou, G., Sutter, G., Tscherne, A., et al. (2025) · Journal of General Virology · doi:10.1099/jgv.0.002180 · Cited by 1
“BNT162b2 by BioNTech/Pfizer, here referred to as mRNA, is a licensed vaccine consisting of nucleoside-modified mRNA also encoding the prefusion-stabilized S protein, formulated in lipid nanoparticles [2].”
Wang, H. (2021) · Infectious Diseases & Immunity · doi:10.1097/id9.0000000000000020 · Cited by 1
Host Cell Entry and Neutralization Sensitivity of SARS-CoV-2 Lineages B.1.620 and R.1
Sidarovich, A., Krüger, N., Rocha, C., Graichen, L., Kempf, A. M., Nehlmeier, I., Lier, M., Cossmann, A., Stankov, M. V., Schulz, S. R., et al. (2022) · Viruses · doi:10.3390/v14112475 · Cited by 2
Ferrari, L., Compagno, M., Campogiani, L., Teti, E., Mulas, T., Checchi, D., Alessio, G., Caldara, F., Coppola, L., Simone, G., et al. (2022) · Vaccines · doi:10.3390/vaccines10081238 · Cited by 1
“The pivotal phase III trial of BNT162b2 demonstrated that the vaccine is safe and well tolerated [3].”
BackgroundNishikubo, M., Tanaka, Y., Mitsui, S., Doi, T., Hokka, D., Hojo, W., Sakai, H., Funakoshi, Y., Yakushijin, K., Ohji, G., et al. (2023) · Surgery Today · doi:10.1007/s00595-023-02649-1 · Cited by 2
Vaccine-induced immune responses against SARS-CoV-2 infections
Garg, M. K., Maralakunte, M., Kumar, Y., Bhujade, H., Sehgal, I. P., Suri, V., & Garg, S. (2021) · Exploration of Immunology · doi:10.37349/ei.2021.00024 · Cited by 2
“Vaccine Vaccine platform Immunogen Dosage Route Interval Efficacy Overall efficacy Current EUA BNT162b2 Pfizer-BioNTech (US) [81-86] mRNA SP 30 μg, 2 doses IM 21 days 88.”
BackgroundÖver, D., Santana, E., Amaral, E. F. L., Lakkimsetti, C., Kelley, A. E., & Espinoza, D. A. (2025) · PLoS ONE · doi:10.1371/journal.pone.0323815 · Cited by 1
“During the COVID-19 pandemic, vaccines emerged as a highly effective method of providing protection against the wild type SARS-CoV-2 [1,2].”
Impact of mRNA and Inactivated COVID-19 Vaccines on Ovarian Reserve
Karaman, E., Yavuz, A., Karakaş, E., Balcıoğlu, E., Karaca, B., Doganay, H. N., Saçıntı, K. G., & Yıldız, O. (2025) · Vaccines · doi:10.3390/vaccines13040345 · Cited by 3
“To ensure biologically relevant effects, ovarian tissue was collected four weeks after the second vaccine dose, aligning with peak immune activation observed in both humans and rodents [61,64].”
Tuba, S., Widyati, W., & Sulaiman, S. A. S. (2021) · Preprints.org · doi:10.20944/preprints202104.0468.v1 · Cited by 1
“3 ml divided into 2 doses, each -70 0 C = 6 months 2 - 8 0 C = 5 days USA and Germany (Polack et al., 2020) Preprints (www.”
BackgroundExploring Effective Therapeutic Approaches for COVID-19: A Review on Progress and Prospects
Okeowo, O. M., Olung, N. F., Ijomone, O. M., & Adeagbo, A. S. O. (2023) · Coronaviruses · doi:10.2174/0126667975267776231117052825 · Cited by 1
Uwamino, Y., Yokoyama, T., Sato, Y., Tanaka, S., Kamoshita, Y., Shibata, A., Kurafuji, T., Tanabe, A., Arai, T., Ohno, A., et al. (2025) · Vaccines · doi:10.3390/vaccines13070751 · Cited by 2
“To mitigate the spread of the virus and the severity of the disease, numerous highly effective vaccines have been developed [1,2].”
Improving Tuberculosis Vaccine Trial Efficiency: A Tough Nut to Crack
McShane, H. (2023) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiad360 · Cited by 1
Peters, M. Q., Young, A. L., Stolarczuk, J. E., Glad, M., Layton, E. D., Logue, J. K., Minkah, N. K., Chu, H. Y., Englund, J. A., Sather, D. N., et al. (2025) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaf599 · Cited by 2
“…comparison studies indicated that mRNA vaccines induced comparable anti-spike IgG titers in infants and adults [2, 3], but efficacy against symptomatic COVID-19 was only 75.8% in children aged 6 months to 2 years for BNT162b and 50.6% for mRNA-1273 [2, 3], lower than early studies in adults [4, 5].”
InfluentialDevelopment of lipid nanoparticles and liposomes reference materials (II) - Cytotoxic profilesPreprint
Syama, K., Jakubek, Z. J., Chen, S., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1933757/v1 · Cited by 1
Lee, H.-J., Hwang, Y.-C., Lee, K.-H., Yim, T., Jung, S.-Y., Park, S.-U., Park, J., Ko, C., & Cho, S. (2022) · 대한한의학회지 · doi:10.13048/jkm.22025 · Cited by 1
A metabolic boost to mRNA vaccines
Chada, N. C., & Wilson, J. T. (2026) · Nature Materials · doi:10.1038/s41563-026-02628-0 · Cited by 1
Effect of BNT162b2 antigen dosage on protection against SARS-CoV-2 omicron infectionPreprint
Chemaitelly, H. S., Ayoub, H. H., Coyle, P. V., Tang, P., Yassine, H. M., Thani, A. A. A., Al-Khatib, H. A., Hasan, M. R., Kanaani, Z. A., Al‐Kuwari, E., et al. (2022) · medRxiv · doi:10.1101/2022.11.29.22282864 · Cited by 1
Dulska, J., Fol, M., & Druszczyńska, M. (2026) · Vaccines · doi:10.3390/vaccines14070560 · Cited by 1
“Advances in vaccine technologies, including mRNA and viral vector platforms, have demonstrated considerable potential for rapid response to emerging pathogens [27,28].”
RNA-based Therapeutics: Master Regulator for Bioengineering Systems in Medicine World
Singla, R., Arora, M., & Bansal, P. (2023) · Current Biotechnology · doi:10.2174/2211550112666230417100541 · Cited by 1
Incidence, Risk Factors and Mortality of COVID-19 among Cancer Patients: A Meta-Analysis
Kombo, A. F., & Ji, X.-Y. (2024) · EAS Journal of Medicine and Surgery · doi:10.36349/easjms.2024.v06i06.001 · Cited by 1
Maciejewska-Radomska, A., Czernia, P., Piotrowska, M., Wajda, B., Słomiński, B., Romantowski, J., Sudoł, A., Dabrowska, M. E., Górska, L., Smiatacz, T., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1436491 · Cited by 1
Bernardes, B. G., Moura, A. D., Guarnieri, J. P. D. O., da Silva, C. F. M., Costa, H. C. M., da Silva, I. G. M., Cordeiro, K. B. B., Báo, S. N., Prudêncio, C. R., & Lancellotti, M. (2024) · The Brazilian Journal of Infectious Diseases · doi:10.1016/j.bjid.2024.104479 · Cited by 1
Ugel, S., Gupta, A., Spiteri, G., Marchetti, P., Sanctis, F. D., Wouters, S., Konnova, A., Monaco, M. G. L., Carta, A., Pezzani, M. D., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1707449 · Cited by 1
Gutschner, T. (2023) · RNA Biology · doi:10.1080/15476286.2022.2161704 · Cited by 1
Altable, M. (2024) · Preprints.org · doi:10.20944/preprints202403.0572.v1
Pařenica, J., Benešová, K., Radvan, M., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4139393 · Cited by 1
Yamada, T., & Shi, S. (2021) · medRxiv · doi:10.1101/2021.08.02.21261486 · Cited by 1
Salmen, A., Marti, S., Hoepner, A. G. F., Chan, A., & Hoepner, R. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1186404 · Cited by 1
“The efficacy and safety of SARS-CoV-2 vaccines has been studied on population-level within the scope of the pivotal vaccination trials (Polack et al., 2020; Baden et al., 2021), and for the general population in large-scale observational studies during mass vaccination campaigns (Dagan et al.”
BackgroundSakamoto, Y., & Watanabe, R. (2024) · The Journal of Dermatology · doi:10.1111/1346-8138.17513 · Cited by 1
Serrano-Ortiz, Á., Romero‐Cabrera, J. L., Villatoro, J. M., Ramos, J., Ruiz-Montero, R., Ritoré, Á., Dopazo, J., Salas, J. D. D., Sánchez, V. G., Salcedo-Leal, I., et al. (2024) · Journal of Epidemiology and Global Health · doi:10.1007/s44197-024-00298-2 · Cited by 2
“Subsequent real-world data studies further affirmed these findings, reinforcing the vital contribution of these vaccines to the ongoing battle against COVID-19 [ 36, 37].”
Okoye, C., Zazzara, M. B., Ceolin, C., Fedele, G., Palmieri, A., Abbatecola, A. M., Malara, A., Trevisan, C., Timmons, S., Prato, R., et al. (2024) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2024.105251 · Cited by 1
Mavridis, C., Aidonidis, G., Arapoglou, D., & Kalogeridis, A. (2022) · Qeios · doi:10.32388/h4xgp2.3
Lu, B., Chaudhary, O., Banoth, B., Nadkarni, J., Zong, W., Mausser, E., Danz, H., Motwani, M., Ruiz, S., Zhang, D., et al. (2025) · Vaccines · doi:10.3390/vaccines13030263 · Cited by 2
“…illness from coronavirus dis-Vaccines 2025 , 13 , 263 https://doi.org/10.3390/vaccines13030263 Vaccines 2025 , 13 , 263 2 of 18 ease (COVID-19) [1,2]. mRNA vaccines can be developed quickly using a standardized production platform, are simpler to manufacture than conventional vaccines, and have…”
InfluentialDifferent immunological responses following immunization with two mRNA vaccines
Nakayama, T., Takai‐Todaka, R., Sawada, A., Ito, T., Fujino, M., Haga, K., & Katayama, K. (2023) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2023.11.020 · Cited by 1
Ahmad, J., Khan, I., & Khan, M. K. (2026) · Lecture notes in nanoscale science and technology · doi:10.1007/978-3-032-04008-4_9 · Cited by 1
IVF outcomes pre- and post-anti-COVID-19 vaccination – Are there any differences?
Fradkin, M. A., Alexandroni, H., Eldar‐Geva, T., & Ben‐Ami, I. (2024) · Reproductive Biology · doi:10.1016/j.repbio.2024.100879 · Cited by 1
SARS- CoV-2 viroporins: A multi-omics insight from nucleotides to amino acidsPreprint
Sarkar, M., Etheimer, P., Hannothiaux, V., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.09.26.461873 · Cited by 1
“Vaccines have been developed using various technologies which have been approved by FDA like ChAdOx1 nCoV- 19 (AstraZeneca) (1), mRNA-1273 (Moderna) (2), BNT162b2 (Pfizer) (3,4), Janssen Ad26.”
MethodNår spydspissen blir liggjande i skuffen
Bakke, B. (2021) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.21.0212 · Cited by 1
Soh, W. W. M., Finol, E., Chan, S. J. W., Zhu, J., Liau, S. S. J. K., Bier, A., Ooi, E. E., & Bazan, G. C. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202405048 · Cited by 2
Chen, W., Hu, S.-Y., Cheng, C., Shen, C., Chuang, H.-Y., Ker, C.-R., Sun, D.-J., & Shen, C. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1358967 · Cited by 1
The Covid Virus Infection a Critical Review of the Whole Affair: Personal Opinion
Riccardi, B., & Resta, S. (2021) · International Journal of Clinical Skills · Cited by 1
Sukik, L., Chemaitelly, H. S., Ayoub, H. H., Coyle, P. V., Tang, P., Hasan, M. R., Yassine, H. M., Thani, A. A. A., Kanaani, Z. A., Al‐Kuwari, E., et al. (2025) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2024-002718 · Cited by 2
“58 However, these antibodies decline over time, 55 59 60 potentially leading to waning protection against asymptomatic and symptomatic rein-fections.”
Rosenthal, J. A., Papa, M. P., Sanz, M., Nicholes, S., Holmberg, C. S., Bosque, A., Keswani, A., AMDUR, R. L., Lynch, R. M., Soriano-Sarabia, N., et al. (2023) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2023.01.025 · Cited by 1
Zhai, Y., Ku, M., Yang, K., Patil, A., Prabhala, P., He, L., Man, Y., Rahman, M., Menon, K., Spörri, S. B., et al. (2026) · iScience · doi:10.1016/j.isci.2026.116416 · Cited by 6
“1,2 The Moderna and BioNTech mRNA vaccines against COVID-19 comprise uridine-modified, non-replicating mRNAs that encode SARS-CoV-2 spike proteins.”
Katzenstein, T. L., Jørgensen, S. E., Mortensen, J., Helleberg, M., Kalhauge, A., & Mogensen, T. H. (2021) · Journal of Medical Case Reports · doi:10.1186/s13256-021-03113-9 · Cited by 1
Bayrak, A., Tıngır, M., Aslantaş, F. Ç., Kural, C., Kantarcı, M., & Çatal, T. (2023) · International Orthopaedics · doi:10.1007/s00264-023-05966-9 · Cited by 1
The Effect of COVID-19 Vaccinations in 47 European Countries
Cornelli, U., & Belcaro, G. (2021) · European Journal of Medical and Health Sciences · doi:10.24018/ejmed.2021.3.3.889 · Cited by 1
Development and Preclinical Evaluation of Virus Like Particle Vaccine Against COVID-19 InfectionPreprint
Ismail Yilmaz, C., İpekoğlu, E. M., Bulbul, A., Turay, N., Yıldırım, M., Evcili, İ., Yilmaz, N. S., Aydin, Y., Guvencli, N., Gungor, B., et al. (2021) · Authorea · doi:10.22541/au.162615692.26217047/v1 · Cited by 1
Peptide-modified lipid for organ-specific mRNA delivery
Li, M., & Li, H. (2025) · BME Horizon · doi:10.70401/bmeh.2025.0006 · Cited by 3
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.